Background/Aims: microRNAs (miRNAs) are noncoding RNAs that regulate multiple targets through either the degradation of mRNAs or the inhibition of protein translation, thereby altering several functions simultaneously. Growing evidence indicates that miRNAs are involved in carcinogenesis and tumor progression in non-small-cell lung cancer (NSCLC). Methods: In this study, the mRNA expression levels of miR-148a were examined in NSCLC cell lines and patient specimens using quantitative reverse transcription-PCR. The functions of miR-148a in migration/invasion and lung metastasis formation were determined by using transwell and tail vein injection assays, respectively. Results: We demonstrated that miR-148a was downregulated in NSCLC metastatic samples, and its expression was suppressed in NSCLC compared with the corresponding nonmalignant lung tissues. Clinical analysis indicated that miR-148a expression was lower in NSCLC patients compared with nonmalignant lung tissues . Decreased miR-148a was significantly associated with tumor node metastasis stage and lymph node metastasis. Furthermore, functional assays showed that miR-148a expression suppressed NSCLC cell invasive and migratory abilities in vitro and suppressed cancer metastasis in vivo, while inhibition of miR-148a enhanced NSCLC cell invasion and lung metastasis formation in a mouse model. Conclusions: Evidence from this study demonstrated that miR-148a exerts tumor-suppressive effects in NSCLC and suggests a new therapeutic option for NSCLC.
MicroRNA-148a Suppresses Invasion and Metastasis of Human Non-Small-Cell Lung Cancer
Introduction miRNAs are non-coding, single-stranded RNAs of ~22 nucleotides that constitute a novel class of gene regulators [1] . The majority of miRNAs lead to translational repression or mRNA degradation through low complementary base-pairing with the 3'UTRs of the target genes [2] . However, some experimental studies have identified miRNA target sites in the coding regions of genes [3] . A single miRNA may target multiple mRNAs, and a single mRNA may have binding sites for multiple miRNAs [1] , thus creating a complex regulatory system for biological processes, such as tumor suppressors and oncogenes [4] .
A recent study showed that approximately 50% of annotated human miRNAs are located in areas of the genome, known as fragile sites, which are associated with cancer. This finding indicates that miRNAs might have a crucial function in cancer progression [5] . In addition, accumulating evidence has implicated miRNAs in the invasion and metastasis of a variety of cancers, including gastric cancer, breast cancer, and hepatocellular carcinoma [6] [7] [8] [9] . In NSCLC, only a few miRNAs have been identified , including miR-4500, miR-4782-3p, miR-193a,miR-30c ,miR-138, and so on [10] [11] [12] [13] [14] . Thus, a better understanding of the changes in miRNA expression during NSCLC invasion may lead to a better understanding of NSCLC development, as well as to possible improvements in the diagnosis and treatment of NSCLC.
In a previous study, we established a highly invasive cell subline (SPC-A-1sci) from a weakly invasive cell subline (SPC-A-1) through in vivo selection in NOD/SCID mice [15] . We compared the global miRNA profiles of SPC-A-1sci and SPC-A-1 cells to identify miRNAs that are potentially involved in human NSCLC invasion. A total of 117 miRNAs were differentially expressed in SPC-A-1sci cells relative to SPC-A-1 cells, and miR-148a expression was significantly down-regulated in SPC-A-1sci cells. Recently, miR-148a expression has been reported in several tumors, including gastric cancer, hepatocellular carcinoma, and pancreatic cancer [8, [16] [17] [18] . Studies have shown that miR-148a suppresses epithelial-to-mesenchymal transition in non-small cell lung cancer cells [19, 20] . However, the potential roles and related target genes of miR-148a in human NSCLC metastasis are still poorly understood.
Materials and Methods

Cell culture
The human lung cancer cell line SPC-A-1 was obtained from Cellular Institute of Chinese Academy of Science(Shanghai, China). SPC-A-1 was originally isolated from the surgical specimens of a Chinese man with advanced lung adenocarcinoma by Shanghai Chest Hospital and Cellular Institute of Chinese Academy of Science [21] . The highly invasive human lung cancer cell line SPC-A-1sci was established by Ming Yao (Shanghai Jiaotong University, Shanghai Cancer Institute) [15] . A549 and H1299 LC-2, and H358cell were maintained in our laboratory. All cell lines were routinely maintained in DMEM (HyClone) supplemented with 10% fetal bovine serum (Biowest, South America Origin), 100 U/ml penicillin sodium, and 100 mg/ml streptomycin sulfate at 37°C in a humidified air atmosphere containing 5% CO 2 . Cells were used when they were in the logarithmic growth phase.
Cell transfections
The miR-148a mimics and miR-148a inhibitors used in this study were synthesized by Ribobio (Guangzhou, China). Oligonucleotide transfection was performed using Lipofectamine 2000 reagents according to the manufacturer's instructions (Invitrogen, CA). For migration, invasion, Western blotting assays, and real-time quantitative RT-PCR (qRT-PCR), the cells were collected 48 h after transfection.
Wound-healing assays
For the cell motility assay, cells expressing the miR mimic, the miR inhibitor, the miR control and the negative control were seeded in six-well plates to approximately 90% confluence. A straight scratch in the cell monolayer was carefully performed using a 200µl pipette tip to create a wound. The cells were rinsed with PBS and cultured with 1% FBS in DMEM. The wounded monolayers were then photographed at 0, 24, and 48 h using a CKX41 microscope (Olympus, Japan) after wounding. The percentage of wounded area that was filled was calculated as follows: {(mean wounded breadth -mean remaining breadth)/mean wounded breadth} ×100%.
In vitro migration and invasion assays
Cell migration and invasion assays were performed in a 24-well plate with 8-mm pore size chamber inserts (Corning, New York, NY, USA). For migration assays, 5 × 10 4 cells expressing miR-control, negative control, miR mimic and miR inhibitor were placed into the upper chamber per well with the non-coated membrane. For invasion assays, 1 × 10 5 cells expressing miR-control, negative control, miR mimic and miR inhibitor were placed into the upper chamber per well with a Matrigel-coated membrane, which was diluted with serum-free culture medium. In both assays, the cells were suspended in 200 µl of DMEM without fetal bovine serum when they were seeded into the upper chamber. The lower chamber contained 800 µl of DMEM supplemented with 10% fetal bovine serum. After incubation for some hours at 37°C and 5% CO 2 , the membrane inserts were removed from the plate, and the non-invading cells were removed from the upper surface of the membrane. The cells that had moved to the bottom surface of the chamber were fixed with 100% methanol for 20 min and stained with 0.1% crystal violet for 30 min. Then, the cells were imaged and counted in at least 10 random fields using a CKX41 inverted microscope (Olympus, Tokyo, Japan). The assays were conducted three independent times.
Establishing stable NSCLC cells
The miR-148a lentiviral vector, miR-148a inhibitor lentiviral vector and miR-control lentiviral vector were synthesized by Genepharma.
In vivo assays for metastasis
For the in vivo metastasis assays, SPC-A-1sci cells stably expressing miR-control or miR-148a lentiviral vector, SPC-A-1 cells transfected with miR-control or miR-148a inhibitor lentiviral vector were inoculated into the tail vein of five-week-old BALB/C-nu/nu nude mice, and the animals were maintained under specific pathogen-free (SPF) conditions. The mice were manipulated and housed according to protocols approved by the Shanghai Medical Experimental Animal Care Commission. Each tumor cell subline was injected into twelve mice (2 × 10 6 per mouse). After eight weeks, the mice were sacrificed, and the lungs were harvested at necropsy and fixed in 10% neutral PB-buffered formalin (pH 7.4). The fixed samples were then embedded in paraffin, and five non-sequential serial sections were obtained per animal. The sections were stained with H&E and analyzed for the presence of metastases.
RNA isolation and qRT-PCR assays
miRNA was extracted from human tissue samples and cultured cells using mirVana miRNA Isolation Kit (Ambion, Carlsbad, CA, USA). The expression level of mature miRNAs was separately quantified with specific primers and probes using TaqMan miRNA assays (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions and normalized to U6 small nuclear RNA. The assay IDs are as follows: hsa-miR-148a, ID 000470; RNU44, ID001094.
Human NSCLC tissues
Patient samples in this study were obtained following informed consent, according to an established protocol approved by the Ethic Committee of Shanghai Jiao-Tong University School. The data did not contain any information that may lead to patient identification. A total of 73 NSCLC tissues and matched adjacent noncancerous tissues for RNA extraction was collected at the time of surgery between 2011 and 2012 at the Department of Lung Cancer, Shanghai Chest Hospital affiliated to Shanghai Jiao Tong University (Shanghai, China). Upon resection, human surgical specimens were immediately frozen in liquid nitrogen and stored at -80°C. Of these 73 NSCLC tissues, 16 were squamous cell carcinomas, and 57 were non squamous cell carcinomas.
Statistical analyses
The results are presented as the mean ± SD. Comparisons of quantitative data were analyzed by Student's t-test between two groups (two-tailed; P < 0.05 was considered significant). Chi-square test was used to compare qualitative variables. Analysis was performed with SAS 9.0 for Windows.
Results
MiR-148a expression is downregulated in NSCLC and associated with advanced clinical stage and NSCLC metastasis
To identify metastasis-related miRNAs, we used an miRNA array on SPC-A-1sci and SPC-A-1 cells. After verifying the results through qRT-PCR, we found low expression levels of miR-148a in SPC-A-1sci cells [12] . To further understand the potential biological significance of altered miR-148a expression in NSCLC progression, we evaluated miR-148a expression in 73 pairs of human NSCLC tissues and their corresponding non-tumor tissues by qRT-PCR.The relationship between the miR-148a expression levels and the clinicopathological characteristics of the NSCLC patients is summarized in Table 1 . The results showed no significant correlations between miR-148a expression and age, gender, or tumor size. We also found that miR-148a expression in NSCLC tissues was lower than in non-tumor tissues and was negatively associated with poorly differentiated tumors, advanced clinical stage, and lymph node metastasis. miR-148a expression was significantly decreased in 42 of 73 tumor samples (55%, Fig. 1A ) compared with the matched normal compartments (Fig. 1B) . In addition, we observed a significant decrease in miR-148 expression in NSCLC with clinical advanced stage (3/4AB, n = 37) compared with those in early stage (1/2AB, n = 36; Fig. 1C ). Furthermore, miR-148a expression was lower in NSCLC patients with lymphatic metastasis (n = 30) and distant metastasis (n = 9) compared with those without lymphatic metastasis (n = 34; Fig. 1D ). Taken together, our results indicate that decreased miR-148a expression in NSCLC was associated with advanced clinical stage and lymph node metastasis.
miR-148a inhibits human NSCLC cell invasion and metastasis in vitro.
To clarify the significance of miR-148a in human NSCLC metastasis, we investigated miR-148a expression in 6 human NSCLC cell lines (A549, H1299, SPC-A-1sci, SPC-A-1, LC-2, than that of SPC-A-1, LC-2 and H358 cells using transwell assays with or without Matrigel [12] . These results showed that miR-148a expression was significantly up-regulated in highly metastatic lung cancer cells (A549, H1299 and SPC-A-1sci) compared with weakly metastatic lung cancer cells (SPC-A-1, LC-2 and H358).
On the basis of the results showing the suppression of miR-148a expression in high metastatic NSCLC cells, SPC-A-1sci, H1299, and A549 cells were transfected with miR148a mimics (Fig. 2B) . The invasion and migration of SPC-A-1sci, H1299, and A549 cells, which were infected with miR-148a mimics, were significantly suppressed compared with the control cells (Fig. 3A, C, D) . SPC-A-1,LC-2,H358 cells infected with miR-148a inhibitors (Fig. 2C) showed increased cell invasion and migration (Fig. 3B, E, F) . Subsequently, woundhealing assays were applied to determine the migratory abilities of miR-148a, and we also observed that A549, H1299, and SPC-A-1sci cells expressing miR-148a mimics exhibited reduced migration rates compared with the controls (Fig. 4A, C, D) . In contrast, miR-148a loss-of-function in SPC-A-1, and LC-2 enhanced the migration rate (Fig. 4B, E) ,miR-148a loss-of-function in H358 did not enhanced the migration rate (Fig. 4F) .Further, we found that up-regulated miR-148a expression significantly enhanced SPC-A-1sci cell growth and clonogenicity (Fig. 5A, C) , and down-regulated miR-148a expression inhibited SPC-A-1 cell growth and clonogenicity compared with the miR-control (Fig. 5B, D) . These observations suggested that miR-148a promoted human NSCLC cell growth in vitro.
Over-expression of miR-148a impairs the metastasis formation in vivo
To further investigate the function of miR-148a during tumor metastasis in vivo, SPC-A-1 cells transfected with the miR-148a inhibitor or the miR-control inhibitor lentiviral vector Fig. 3 . Transwell migration and invasion assays. (A-F) Transwell migration and invasion assays for SPC-A1sci, H1299, A549, SPC-A-1,LC-2,H358 were determined after transduction with miR controls, miR-148a, anti-miR controls, and anti-miR-148a.The data are representative of three independent experiments. The error bars represent the s.e.m. * P < 0.05; ** P < 0.01; *** P < 0.001 by Student's t-test. Fig. 4 . Wound-healing assay. (A-F) Wound-healing assay for SPC-A-1sci, H1299, A549, SPC-A-1,LC-2,H358 after transduction with the miR controls, miR-148a, anti-miR controls, and anti-miR-148a. The data are representative of three independent experiments. The error bars represent the s.e.m. * P < 0.05; ** P < 0.01; *** P < 0.001 by Student's t-test. and SPC-A-1sci cells with miR-148a or the miR-control lentiviral vector were injected into nude mice through the lateral tail vein (n = 12; Fig. 6 ). Metastatic tumors was significantly decreased in mice that were injected with SPC-A-1sci cells with the miR-148a lentiviral vector compared with the control group after eight weeks. In stark contrast, lung metastasis was apparent in mice injected SPC-A-1 cells transfected with the miR-148a inhibitor lentiviral vector compared with the negative control group after twelve weeks (Fig. 7A, B) . In addition, the ratio of lung metastasis in the miR-148a lentiviral vector group was markedly lower than that of the controls. Conversely, the metastasis rates in the miR-148a inhibitor lentiviral vector group were markedly higher than those in the negative control group (Fig. 7C) . Taken together, these results suggest that miR-148a is a negative regulator of NSCLC metastasis.
Discussion
Metastasis is responsible for the failure of lung cancer therapy and the poor prognosis of lung cancer patients. Therefore, it is essential for us to identify the metastatic factors and understand the molecular mechanisms underlying NSCLC. Growing evidence suggests that miRNAs have important roles in carcinogenesis and metastasis [22] . In the present study, we identified 117 novel metastasis-related miRNAs in NSCLC based on a well-established metastasis cell model [12] , and we found that miR-148a was significantly down-regulated in highly metastatic cells.
Previous studies on miR-148a have yielded various results in different cancers. Clinical studies have shown that miR-148a expression is an independent prognostic/predictive biomarker for advanced colorectal cancer patients [23] . Another report showed that miR148a attenuates the paclitaxel resistance of hormone-refractory prostate cancer [24] . In addition, miR-148a promotes apoptosis in colorectal cancer, promotes cell proliferation in gastric cancer, inhibits angiogenesis in breast cancer, and suppresses tumor cell invasion and metastasis in hepatocellular carcinoma and gastric cancer [16, [25] [26] [27] [28] . These findings indicate that miR-148a may have important functions in human carcinogenesis. In our study, we observed that miR-148a could suppress the migration and invasion of NSCLC cells in vitro and metastasis in vivo. In addition, miR-148a promoted NSCLC cell proliferation. We also showed that miR-148a was down-regulated in NSCLC tissue samples compared with the corresponding non-cancerous tissues. Furthermore, miR-148a expression was lower in the NSCLC tissue samples with advanced clinical stage and lymph node metastasis. On the basis of these data, we speculated that miR-148a suppressed tumor cell invasion and metastasis in NSCLC.
In summary, miR-148a could suppress NSCLC invasion and metastasis. Importantly, these findings might provide a promising therapeutic target in NSCLC. Li 
